High Expression of Complement Component 5 ( C5 ) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients
ISRN Oncology · 2011
DOI: 10.5402/2011/168712 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Oncology, 2011. Verfasst von Suvi Savola und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, 00014, Helsinki, Finland. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Background
Unlike in most adult-onset cancers, an association between typical paediatric neoplasms and inflammatory triggers is rare. We studied whether immune system-related genes are activated and have prognostic significance in Ewing's sarcoma family of tumors (ESFTs).
Method
Data analysis was performed on gene expression profiles of 44 ESFT patients, 11 ESFT cell lines, and 18 normal skeletal muscle samples. Differential expression of 238 inflammation and 299 macrophage-related genes was analysed by t -test, and survival analysis was performed according to gene expression.
Results
Inflammatory genes are activated in ESFT patient samples, as 38 of 238 (16%) inflammatory genes were upregulated ( P < 0.001 ) when compared to cell lines. This inflammatory gene activation was characterized by significant enrichment of macrophage-related gene expression with 58 of 299 (19%) of genes upregulated ( P < 0.001 ) . High expression of complement component 5 ( C5 ) correlated with better event-free ( P = 0.01 ) and overall survival ( P = 0.004 ) in a dose-dependent manner. C5 and its receptor C5aR1 expression was verified at protein level by immunohistochemistry on an independent ESFT tumour tissue microarray.
Conclusion
Immune system-related gene activation is observed in ESFT patient samples, and prognostically significant inflammatory genes ( C5, JAK1 , and IL8 ) for ESFT were identified.
Autor:innen und Institutionen
- Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, 00014, Helsinki, Finland.
Zitieren
APA
Savola, S., Klami, A., Myllykangas, S., Manara, C., Scotlandi, K., Picci, P., Knuutila, S., & Vakkila, J. (2011). High Expression of Complement Component 5 ( C5 ) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients. ISRN Oncology. https://doi.org/10.5402/2011/168712
Vancouver
Savola S, Klami A, Myllykangas S, Manara C, Scotlandi K, Picci P, et al. High Expression of Complement Component 5 ( C5 ) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients. ISRN Oncology. 2011. doi:10.5402/2011/168712
BibTeX
@article{Savola2011,
author = {Savola, Suvi and Klami, Arto and Myllykangas, Samuel and Manara, Cristina and Scotlandi, Katia and Picci, Piero and Knuutila, Sakari and Vakkila, Jukka},
title = {High Expression of Complement Component 5 ( C5 ) at Tumor Site Associates with Superior Survival in Ewing's Sarcoma Family of Tumour Patients},
journal = {ISRN Oncology},
year = {2011},
doi = {10.5402/2011/168712}
}
EUVIMED